^
Association details:
| Biomarker: | NRAS G12C + BRAF mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Excerpt:
Cell line pools became resistant to high-dose PLX4032 (10 μmol/L) or GSK1120212 (1 μmol/L), as evidenced by robust proliferation in the presence of inhibitor (data not shown). Acquired activating mutations in KRASG13D or NRASG12C were identified in PLX4032-resistant BRAF-mutant A375 melanoma (Fig. 3A and B) or PLX4032-resistant BRAF-mutant RKO colorectal (Supplementary Fig. S6) lines, respectively.
DOI:
10.1158/2159-8290.CD-13-0070
